Analysts Rate Piramal Healthcare Best Play On Innovator CRAMS
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Piramal Healthcare was rated by Citigroup Analysts as India's best play on innovator CRAMS, following its FY09 earnings call July 24
You may also be interested in...
Piramal Healthcare Buys Rights To Sell Germany’s PlasmaSelect
NEW DELHI - India's Piramal Healthcare said it has bought the global rights to market blood plasma products of Germany-based PlasmaSelect for an undisclosed amount in a deal that excludes the company's manufacturing unit at Marburg, Germany
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).